FDA Approves Dostarlimab Combination for Primary Advanced or Recurrent Endometrial Cancer
August 1st 2023Dostarlimab-gxly (Jemperli) approved in combination with carboplatin and paclitaxel for the treatment of adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient.
Read More
Immunoprophylaxis Guidance for RSV Not Aligned With Current Hospitalization Patterns, Study Finds
July 12th 2023Investigators urge policymakers to establish flexible models that maximize coverage when respiratory syncytial virus activity is high and minimize unnecessary doses when viral activity is low.
Read More
ACIP Votes to Recommend Use of Arexvy for Respiratory Syncytial Virus in Older Adults
June 22nd 2023CDC Advisory Committee on Immunization Practices recommends the use of respiratory syncytial virus (RSV) vaccine, adjuvanted (Arexvy) for adults 60 years of age and older based on findings from the first season of the pivotal AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial.
Read More
Obstructive Sleep Apnea May Have Significant Impact on Cognitive Decline in Middle-Aged Individuals
June 6th 2023Recent debates have surrounded whether cognitive deficits, specifically in middle-aged patients, may be driven by cardiovascular and metabolic comorbidities instead of distinct obstructive sleep apnea processes.
Read More